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relationship between the severity of diastolic dysfunction, and get
plasma NT-proBNP in the diagnosis of diastolic heart failure most
good community values.
METHODS The study is outpatient or inpatient treatment of non-
systolic heart failure in patients with hypertension 61 cases were
divided into three groups: no clinical signs and symptoms of heart
failure, echocardiography without diastolic dysfunction group I;
clinical None signs and symptoms of heart failure, echocardiographic
diastolic dysfunction group II; clinical signs and symptoms of heart
failure, echocardiographic diastolic dysfunction group III. In 20
healthy control group. All patients enrolled in clinical data are
collected to determine the presence or absence of heart failure, and
cardiac function NYHA classiﬁcation. 24 hours of admission or treat-
ment echocardiography expert to determine whether the diastolic
dysfunction and diastolic function of the extent of becoming divided
into four weight: I level (normal diastolic function), grade II (impaired
relaxation), III grade (pseudo- normalization ﬁlling), grade IV
(restrictive ﬁlling). Admission or treatment plasma NT-proBNP con-
centrations within 24 hours. Comparison between different experi-
mental groups, between different classiﬁcation of diastolic function,
plasma NT-proBNP levels between different NYHA class; evaluate the
relationship between echocardiographic indices of diastolic function
and plasma NT-proBNP for; were constructed NT-proBNP diagnostic
diastolic dysfunction and diastolic ROC curve of heart failure, and
were the best diagnostic cutoff value.
RESULTS The area under the ROC curve of plasma NT-proBNP diag-
nosis of diastolic heart failure (AUC) was 0.886 (95% CI 0.818-0.954,
P ¼ 0.000). Plasma NT-proBNP when 112.45pg/ml, diastolic heart
failure diagnostic sensitivity 94.0%, speciﬁcity 81.8%, positive pre-
dictive value of 72.7%, negative predictive value of 94.6%.
CONCLUSIONS The plasma NT-proBNP for diagnosis of diastolic heart
failure is valuable.
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OBJECTIVES B-type natriuretic peptide (BNP) and N-terminal pro-B-
type natriuretic peptide (NT-proBNP) are increasingly being used to
guide the management of acute heart failure (AHF) patients. This
study aims to explore some new biomarkers providing predicting
values for short term prognosis in patients with AHF.
METHODS A total of 206 patients with AHF were enrolled and fol-
lowed for 3 months. Baseline level of complete blood count, complete
biochemistry, D-dimer and NT-proBNP were measured at admission
or the following morning. Primary endpoints of the study were car-
diovascular (CV) events, deﬁned as cardiac death and/or readmission
for AHF.
RESULTS During the 90-day follow-up period, 15 patients died and 10
patients were re-hospitalized due to worsening of heart failure
(12.14%). Red cell distribution width (RDW), D-dimer and NT-proBNP
were signiﬁcantly higher in the patients who had a CV events at the
90-day (p < 0.001). The area under receiver operating characteristic
(ROC) curve (AUC) of NT-proBNP, D-dimer and RDW for predicting CV
events by 90- day was 0.806, 0.887 and 0.754. Kaplan-Meier survival
curve for 90-day CV events showed that patients with a D-dimer level
> 1.1mg/dL and NT-proBNP > 2262.0pg/mL were at high risk (p <
0.001) for short-term outcomes of AHF.
CONCLUSIONS D-dimer could be as a new biomarker combined with
NT-proBNP for predicting early prognostic value to cardiovascular
events of AHF.
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OBJECTIVES Resveratrol can protect the heart from sepsis, but the
detailed mechanism remains unknown; therefore, we try to explore
the mechanism.METHODS FVB and C57BL/6J male mice (age: 8 weeks; body weight:
20-25g) were subjected to lipopolysaccharide (LPS) injection at 6 mg/
kg to set up a sepsis model. One study included 5 groups: Group 1
(control mice); Group 2 (intraperitoneal injection with LPS); Group 3
(treated with resveratrol only for 3 days); Group 4 (treated with
resveratrol for 3 days before LPS); Group 5 (treated with LPS and
resveratrol at same time). These mice were sacriﬁced at 48 h after LPS
treatment. The dose of resveratrol was 20 mg/kg/d. Serial echocar-
diograms were performed to assess cardiac function.
RESULTS In both strains of mice, LPS injection could signiﬁcantly
decrease the left ventricular EF% from 6 to 48 hour. For resveratrol
prevention study, we found that tumor necrosis factor alpha (TNF-a)
levels in plasma and heart tissue were signiﬁcantly increased at 6 h
after LPS injection in groups 2, 4, and 5, compared to the groups 1 and
3. Among the groups 2, 4 and 5 there was no signiﬁcant difference.
CD45 is a pan-leukocyte marker, heart wax section immunohisto-
chemistry staining for CD 45 shows no difference in all groups. Using
immune blot and ELISA to assess the ratio of cleaved caspase 3 to
caspase 3 and plasma level of troponin I, markers for cardiac cell
apoptosis and injury, respectively, showed no difference in all groups,
which indicates that cardiac dysfunction in sepsis is not due to cardiac
cell loss. Time-course comparison between FVB and C57BL/6J mice,
we found that C57BL/6J mice was more susceptible to FVB mice since
the former showed a signiﬁcant decrease (more than 50%) in EF%
while FVB mice showed about 40% decrease in EF%. However, car-
diac dysfunction of C57BL/6J mice showed a faster recovery from 6 to
24 hour compared to FVB that recovered from 6 to 48 hours.
CONCLUSIONS Resveratrol protection of the heart from sepsis is not
due to its prevention of LPS-induced inﬂammation. Since resveratrol
is a multiple bioactive natural compound, we should focus other
mechanisms to explore how resveratrol protect heart from sepsis in
the future studies.
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OBJECTIVES To observe correlation between the standard of N-ter-
minal pro-B-type natriuretic peptide (NT-proBNP) and cardiac func-
tion in different NYHA classiﬁcation, LVEF and LVED.
METHODS For the 83 patients of heart failure in hospital, to assay
their NT-proBNP of blood serum by enzyme-linked immunosorbent
assay (ELISA) and determine their LVEF and LVED by UCG. To analyse
the correlation of patients’ NT-proBNP, the different cardiac func-
tional grading and the indexes above-mentioned.
RESULTS (1) Different NYHA cardiac function classiﬁcation levels of
serum NT-proBNP levels was signiﬁcantly. Its level is positively
correlated with cardiac function. (2) NT-proBNP is negatively corre-
lated with LVEF and positively correlated with the LVED.
CONCLUSIONS NT-proBNP measurement is one of the methods of
effective assistance in clinical diagnosis of heart failure, on the whole
reﬂect the severity of heart failure.
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OBJECTIVES Inﬂammation and dystrophic calciﬁcation have been
associated with cardiovascular disease (CVD) and chronic heart failure
(CHF), changes in pathophysiological functions are reported during
sea level altitude; however, Few study have explored altitude differ-
ence(2260m, 3300m) of change levels of serum high mobility group
box 1 protein (HMGB1), Fetuin-A in patients with congestive heart
failure and effects on ventricular remodeling. The aim of the present
study was to evaluate the effect the altitude difference explore on
HMGB1, Fetuin-A, and to study the relationship between changes of
HMGB1, Fetuin-A and left ventricular mass index (LVMI), mean wall
stress (MWS) and cardiac function.
METHODS A total of 129 consecutive patients with CHF with matched
age and sex were enrolled, and CHF patients were divided into high
altitude group (3300m) (n¼ 62) and moderate altitude group (2260m)
